Insider Buying Signals Amid a Slumping Stock
On May 14, 2026, Paul Bisaro — a senior director at Myriad Genetics Inc. — purchased 7,500 shares of the company’s common stock at $3.69 per share, bringing his post‑transaction holdings to 97,441 shares. While the trade amount is modest relative to the company’s $384 million market cap, it arrives at a pivotal moment: the stock has been under pressure, slipping 11.5 % for the week and 26.3 % for the month, and trading near its 52‑week low of $3.73. The buy is priced just below the close of $3.73, suggesting Bisaro is taking a cautious stance, betting that the company’s fundamentals – particularly its pipeline of molecular diagnostic tests – will rebound.
Insider Activity in Context
The day before Bisaro’s purchase, the company’s chief commercial officer, Brian J. Donnelly, sold 55,975 shares at $4.80, while the chief operating officer, Mark Verratti, sold 2,055 shares at $4.58. A series of senior executives, including the chief scientific officer, Dale Muzzey, and the chief finance officer, Richard Wheeler, have also been active sellers throughout March. Conversely, several executives have been buying, notably CEO Raha Samraat, who added 618,557 shares on March 12 at $0.00 (a block purchase) and later sold 36,304 shares at $4.66. These movements reflect a mix of portfolio rebalancing and potentially market‑timed trades, but the net effect is a slight drift toward lower share ownership by senior management.
What Does This Mean for Investors?
Signal of Confidence, Not a Forecast – Bisaro’s purchase, while modest, may indicate that he believes the stock is undervalued relative to the company’s long‑term prospects. Given Myriad’s negative P/E ratio of –0.96 and its steady decline in share price, this could be seen as a bullish stance in an otherwise bearish environment.
Short‑Term Volatility Likely to Persist – The broader insider selling trend suggests that senior executives may be cash‑constrained or seeking liquidity. Unless the company releases a significant earnings beat or a breakthrough in its diagnostic portfolio, the stock is likely to continue its downtrend, at least in the near term.
Potential Catalyst for a Reversal – If the company can secure new contracts or regulatory approvals, the mix of insider buying (including Bisaro’s recent trade) could help stabilize the price. Investors should monitor any forthcoming FDA filings or commercial launch announcements for potential turning points.
Strategic Takeaway
For portfolio managers and active traders, Bisaro’s buy is a small‑but‑meaningful piece of the insider puzzle. It suggests that at least one senior director sees value in the current valuation, but the prevailing trend of executive selling tempers the enthusiasm. A balanced approach—keeping a close eye on upcoming biotech earnings cycles and regulatory updates—will help investors navigate the continued volatility in Myriad Genetics’ share price.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026-05-14 | Bisaro Paul () | Buy | 7,500.00 | 3.69 | Common Stock |
